Status:
COMPLETED
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side eff...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer.
- Presence of measurable tumor
- Able to swallow medication
Exclusion
- Major surgery within 4 weeks before randomization
- Last dose of prior chemotherapy received less than 4 weeks prior to randomization
- Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)
- Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
- Significant cardiac events
- Previous ZD6474 treatment
Key Trial Info
Start Date :
November 23 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 26 2024
Estimated Enrollment :
331 Patients enrolled
Trial Details
Trial ID
NCT00410761
Start Date
November 23 2006
End Date
July 26 2024
Last Update
September 24 2025
Active Locations (127)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site Number 3
Little Rock, Arkansas, United States, 72205
2
University Arkansas Site Number : 3
Little Rock, Arkansas, United States, 72205
3
Investigational Site Number 8
San Francisco, California, United States, 94115
4
USCF / Mt Zion Medical Center Site Number : 8
San Francisco, California, United States, 94115